What is the recommended starting dose, titration schedule, contraindications, side effects, and monitoring for mirtazapine in an adult with major depressive disorder, especially when insomnia is a primary symptom?

Mirtazapine for Major Depressive Disorder with Insomnia

Start mirtazapine at 15 mg once daily at bedtime, and if inadequate response after 1-2 weeks, increase to 30 mg daily, with a maximum dose of 45 mg daily if needed. 1

Starting Dose and Titration

The FDA-approved starting dose is 15 mg once daily, preferably in the evening prior to sleep 1. This differs from the ultra-low doses (3.75-7.5 mg) sometimes used off-label specifically for insomnia 2, 3, but the standard antidepressant dose is required for treating major depressive disorder.

Titration schedule:

• Start at 15 mg at bedtime
• If inadequate response, increase to 30 mg after 1-2 weeks
• Maximum dose: 45 mg daily
• Do not change doses more frequently than every 1-2 weeks to allow adequate time to assess response 1

The mean effective dose in clinical trials ranged from 18.7-32 mg/day 1, 4, with most patients responding to 15-30 mg daily.

Why Mirtazapine for MDD with Insomnia

Mirtazapine is particularly advantageous when insomnia is a primary symptom because it provides dual benefits: antidepressant efficacy comparable to SSRIs and tricyclics, plus significant improvement in sleep disturbance 5. In one study, 62.4% of patients achieved insomnia remission by 6 weeks, with improvements visible as early as 2 weeks 4.

However, guidelines position mirtazapine as a second- or third-line option for primary insomnia, after benzodiazepine receptor agonists fail 5. For MDD with comorbid insomnia, mirtazapine can be used as first-line therapy since it addresses both conditions simultaneously 5.

Contraindications and Precautions

Absolute contraindications:

• Concurrent use with MAOIs or within 14 days of MAOI discontinuation 1
• Hypersensitivity to mirtazapine

Use with caution in:

• Pregnancy and nursing (not recommended) 5
• Compromised respiratory function (asthma, COPD, sleep apnea) 5
• Hepatic or renal impairment (may require dose reduction) 1
• Elderly patients (consider lower starting doses) 5
• History of bipolar disorder (screen before initiating) 1

Side Effects

Most common adverse effects (>10%):

• Drowsiness/somnolence (23% vs 14% placebo) - paradoxically may decrease at higher doses 6, 7
• Increased appetite (11% vs 2% placebo) 6
• Weight gain (10% vs 1% placebo) 5, 6, 4
• Dry mouth (25% vs 16% placebo) 6

Important advantages over other antidepressants:

• Minimal anticholinergic effects compared to tricyclics 5, 8
• No sexual dysfunction (unlike SSRIs) 8, 7
• No significant cardiovascular effects 8
• Very low seizure risk 6, 7

Rare but serious:

• Agranulocytosis/neutropenia (rare; monitor if fever, sore throat, or infection develops) 6, 7
• Elevated liver enzymes (usually mild and transient) 7

Monitoring

Initial monitoring (first 1-2 weeks):

• Assess for suicidal ideation, agitation, irritability, or unusual behavioral changes 9
• Monitor for therapeutic response and adverse effects 9
• This early monitoring is critical as suicide risk is highest in the first 1-2 months 9

Ongoing monitoring:

• Reassess every few weeks initially, then regularly 5
• If no adequate response by 6-8 weeks, modify treatment 9
• Monitor weight and appetite changes
• Check for signs of infection (fever, sore throat) given rare agranulocytosis risk 6

Response timeline:

• Insomnia improvement: as early as 2 weeks (24.8% remission at day 14) 4
• Depression improvement: significant by 1 week in some studies, with 41.3% achieving remission by 6 weeks 1, 4

Drug Interactions and Dose Adjustments

Reduce mirtazapine dose with:

• Strong CYP3A4 inhibitors (ketoconazole, clarithromycin) 1
• Cimetidine 1

Increase mirtazapine dose with:

• Strong CYP3A4 inducers (carbamazepine, phenytoin, rifampin) 1

Avoid or use extreme caution:

• Alcohol or CNS depressants (additive sedation) 5, 6
• MAOIs (14-day washout required) 1

Discontinuation

Gradually taper rather than stopping abruptly to avoid withdrawal symptoms and rebound insomnia 1. Taper over 10-14 days when discontinuing 2.

Duration of Treatment

• First episode of MDD: continue for 4-9 months after achieving remission 9
• Recurrent depression (≥2 episodes): longer duration may be beneficial 9
• For chronic insomnia with MDD, long-term use may be indicated for severe or refractory cases 5

Clinical Pearls

• The sedating effect is dose-dependent and paradoxically may decrease at higher doses (>15 mg), as higher doses engage more noradrenergic activity 6, 7
• Weight gain and increased appetite are predictable; counsel patients upfront 5, 4
• Mirtazapine's lack of sexual side effects makes it preferable when this is a concern with SSRIs 8, 7
• Safe in overdose (up to 315 mg caused only transient somnolence) 6